A landmark report from the Alzheimer's Society, released in partnership with the Daily Mail's Defeating Dementia campaign, warns that dementia patients are being let down at every stage of their care in a failing system that would never be tolerated for cancer or heart disease. The findings lay bare a crisis of staggering scale, with patients waiting an average of 3.5 years from first symptoms to diagnosis.
System of Delay, Denial, and Neglect
One in five patients report receiving no support after diagnosis, with families describing being 'released into the wild'. Only half of those prescribed dementia medication remain on it for a year, despite the benefits of continued treatment. Michelle Dyson, chief executive of the Alzheimer's Society, said the comparison with cancer care should shame the nation. 'Dementia care in the UK is stuck in a system of delay, denial and neglect,' she said. 'In the digital age of instant answers, people are still waiting far too long for a diagnosis of the country's biggest killer. That would never be tolerated in cancer care, yet for dementia it has become routine.'
Staggering Scale of the Crisis
Around one million people in the UK are living with dementia, a figure set to reach 1.4 million by 2040. The condition already costs Britain £42 billion a year, projected to more than double to £90 billion within fifteen years. According to the Alzheimer's Society's new report, Unlocking the Door, patients are regularly failed by the NHS. Newly-diagnosed dementia patients wait an average of more than five months before being referred to a specialist memory clinic. Only a third of patients are offered cognitive stimulation therapy, group activity sessions proven to improve memory, mood, and daily functioning skills. Access to diagnosis, treatment, and social care services varies depending on postcode.
Drug Rejection and Calls for Action
The findings come almost a year after NHS spending chiefs rejected two new dementia drugs, lecanemab and donanemab, the first-ever medicines proven to slow the progression of the disease. In June 2025, the National Institute for Health and Care Excellence (NICE) rejected them for NHS use in England and Wales, arguing the cost of implementation was 'substantially higher' than considered acceptable for taxpayers' money. In March, NICE agreed to look again at the evidence supporting the rollout of these drugs. The Alzheimer's Society is now calling on the Government to introduce clear national targets, a structured care pathway, and equal access to treatment regardless of postcode, ethnicity, or income.
'This is not a backlog problem,' said Michelle Dyson. 'It is a system that is missing people at every stage and while the system waits, dementia progresses - stealing time, independence and dignity. While politicians race to cut waiting lists, people with dementia aren't even in the queue. Government action can't wait.' NHS England and the Department of Health and Social Care have been approached for comment.
Understanding Dementia
Dementia is an umbrella term for a range of progressive neurological disorders affecting the brain. Alzheimer's disease is the most common type. Some people may have a combination of types. Each person experiences dementia in their own unique way. Dementia is a global concern but is most often seen in wealthier countries where people live into very old age. The Alzheimer's Society reports over one million people in the UK live with dementia, with over 500,000 having Alzheimer's. The number is expected to rise to over 1.4 million by 2040. In the US, there are an estimated 5.5 million Alzheimer's sufferers. Currently, there is no cure for dementia, but new drugs can slow its progression, and earlier diagnosis leads to more effective treatments.
